Among the several endocrine drugs, tamoxifen (Tam), aromatase inhibitors, and other selective ER modulators (SERMs) or downregulators (SERDs) represent the standard treatment for ER+ breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.